Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 401–500 of 1,006
Noz, M. P., Bekkering, S., Groh, L. A., Nielen, T. M., Lamfers, E. J. P., Schlitzer, A., Messaoudi, S. E., van Royen, N., Huys, E., Preijers, F. W. M. B., et al. (2020) · eLife · doi:10.7554/elife.60939 · Cited by 63
“Evidence is rapidly accumulating that chronic low-grade inflammation of the vascular wall is a key pathophysiological component of atherosclerosis, and that treatment with anti-inflammatory drugs, such as canakinumab and colchicine, additionally lowers future CVD risk (Nidorf et al., 2020; Ridker et al., 2017; Tardif…”
BackgroundCoenen, D. M., Heinzmann, A. C. A., Karel, M. F. A., Cosemans, J. M. E. M., & Koenen, R. R. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.12.017 · Cited by 64
Tong, D. C., Bloom, J. E., Quinn, S., Nasis, A., Hiew, C., Roberts-Thomson, P., Adams, H., Sriamareswaran, R., Htun, N. M., Wilson, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.054610 · Cited by 57
Živković, L., Asare, Y., Bernhagen, J., Dichgans, M., & Georgakis, M. K. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317492 · Cited by 74
Lipoprotein (a), Inflammation, and Atherosclerosis
Fusco, S. A. D., Maggioni, A. P., Scicchitano, P., Zuin, M., D’Elia, E., & Colivicchi, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072529 · Cited by 68
“In both studies, (COLCOT and LoDoCo2) patients were enrolled regardless of hsCRP levels.”
InfluentialSelf-citationDrug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
“Two of these trials were completely publicly funded [61, 62].”
BackgroundMach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Gholoobi, A., Askari, V. R., Naghedinia, H., Ahmadi, M., Vakili, V., & Rahimi, V. B. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00865-0 · Cited by 61
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?
Deftereos, S. G., Γιαννόπουλος, Γ., Vrachatis, D. A., Siasos, G., Giotaki, S. G., CLEMAN, M. W., Dangas, G., & Stefanadis, C. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa033 · Cited by 60
“[5] [6] [7] [8] Therefore, it was reasonable that, among others, colchicine would be tested in the context of COVID-19.”
BackgroundPromise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models
Das, B., Sarkar, C., Rawat, V. S., Kalita, D., Deka, S., & Agnihotri, A. (2021) · Molecules · doi:10.3390/molecules26164996 · Cited by 60
“Non-licensed utilities of colchicine are multiple and are inclusive of afflictions such as acute calcium pyrophosphate (CPP) arthritis (pseudogout), sarcoid and psoriatic arthritis, Behcet’s disease, and pericarditis, and of late, experiments have demonstrated colchicine’s capability in obviating leading cardiovascula…”
BackgroundCardiovascular disease risk and pathogenesis in systemic lupus erythematosus
Oliveira, C. B., & Kaplan, M. J. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00922-y · Cited by 72
“In a randomized, double-blinded study of patients who had recent myocardial infarction, daily colchicine usage resulted in a significantly lower risk of CV events compared to placebo [165].”
BackgroundBosmans, L. A., van Tiel, C. M., Aarts, S. A. B. M., Willemsen, L., Baardman, J., van Os, B. W., den Toom, M., Beckers, L., Ahern, D., Levels, J. H. M., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac084 · Cited by 61
Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets
Tănase, D. M., Valasciuc, E., Gosav, E. M., Ouatu, A., Buliga-Finiș, O. N., Floria, M., Maranducă, M. A., & Șerban, I. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098162 · Cited by 70
“Patients with acute coronary syndrome who were administered short-term colchicine in the Colchicine Cardiovascular Outcomes Trial (COLCOT) displayed markedly decreased IL-1 and caspase-1 production when compared to untreated patients, indicating that colchicine has potential atheroprotective effects [155].”
BackgroundResultInflammageing, a targetable pathway for preventing cardiovascular diseases
Aranda, J. F., Ramírez, C. M., & Mittelbrunn, M. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae240 · Cited by 73
“103,109 More recently, conclusions from COLCOT trial have led the European Society of Cardiology to include colchicine as a recommendation for prevention in high-risk patients of CVD 105,106 ( Table 2 ).”
Weber, B., Stevens, E. F., Perez-Chada, L. M., Brown, J. M., Divakaran, S., Bay, C. P., Bibbo, C. F., Hainer, J. M., Dorbala, S., Blankstein, R., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.12.031 · Cited by 59
Tucker, B., Vaidya, K., Cochran, B. J., & Patel, S. (2021) · Cells · doi:10.3390/cells10061391 · Cited by 72
“More recently, the Low Dose Colchicine 2 (LoDoCo2) trial and Colchicine Cardiovascular Outcomes Trial (COLCOT) have demonstrated the efficacy of colchicine, a potent and readily available anti-inflammatory medication, for the secondary prevention of CAD [3,4].”
BackgroundShirakawa, K., & Sano, M. (2022) · Biomedicines · doi:10.3390/biomedicines10081850 · Cited by 65
“A clinical study examining whether double-stranded DNA and MPO DNA in the circulating blood are associated with clinical outcomes and increased coagulability in patients with stable CAD found that only the double-stranded DNA levels were significantly associated with adverse clinical outcomes at 2 years (unstable angi…”
BackgroundInfluentialCho, D. I., Ahn, M. J., Cho, H. H., Cho, M., Jun, J. H., Kang, B. G., Lim, S. Y., Yoo, S. J., Kim, M. R., Kim, H.-S., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00937-x · Cited by 59
Potere, N., Garrad, E. C., Kanthi, Y. M., Nisio, M. D., Kaplanski, G., Bonaventura, A., Connors, J. M., Caterina, R. D., & Abbate, A. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad084 · Cited by 61
Cai, X., Song, S., Hu, J., Wang, L., Shen, D., Zhu, Q., Yang, W., Luo, Q., Hong, J., & Li, N. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s433190 · Cited by 60
Daub, S., Lutgens, E., Münzel, T. F., & Daiber, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228533 · Cited by 60
“In addition, the COLCOT study showed that unspecific anti-inflammatory therapy by colchicine may have cardioprotective effects [23], which was later corroborated by the LoDoCo2 trial which found a reduction in cardiovascular events in patients suffering from CVD who received a daily, low dose of colchicine [24].”
BackgroundBroeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 63
“This beneficial effect was confirmed in two large RCTs in patients after recent myocardial infarction [148], or with chronic coronary disease [105].”
ResultTargeting thromboinflammation in antiphospholipid syndrome
Salet, D. M., Bekkering, S., Middeldorp, S., & van den Hoogen, L. L. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.002 · Cited by 64
Innate immune memory in cardiometabolic disease
Bahrar, H., Bekkering, S., Stienstra, R., Netea, M. G., & Riksen, N. P. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad030 · Cited by 58
“More recently, two randomized controlled trials showed that also the nonspecific anti-inflammatory drug colchicine, traditionally used for the treatment of gout attacks, reduced the major adverse cardiovascular event rate in patients with coronary artery disease.(46,47)”
BackgroundT cells in cardiac health and disease
Martín, P., & Sánchez‐Madrid, F. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185218 · Cited by 65
Hoshino, M., Yang, S., Sugiyama, T., Zhang, J., Kanaji, Y., Yamaguchi, M., Hada, M., Sumino, Y., Horie, T., Nogami, K., et al. (2020) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2020.02.002 · Cited by 53
Molitor, M., Rudi, W., Garlapati, V. S., Finger, S., Schüler, R., Kossmann, S., Lagrange, J., Nguyen, T. S., Wild, J., Knopp, T., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa042 · Cited by 58
Role of Inflammation in Coronary Epicardial and Microvascular Dysfunction
Godo, S., TAKAHASHI, J. C., Yasuda, S., & Shimokawa, H. (2021) · European Cardiology Review · doi:10.15420/ecr.2020.47 · Cited by 57
“1016/S0140-6736(17)32714-9; PMID: 29103656.”
Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Diaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P., & Kjaer, A. (2021) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 53
Kaura, A., Hartley, A., Panoulas, V. F., Glampson, B., Shah, A. S. V., Davies, J., Mulla, A., Woods, K., Omigie, J., Shah, A. D., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003911 · Cited by 57
Hansten, P. D., Tan, M. S., Horn, J. R., Gómez-Lumbreras, A., Zapata, L. V., Boyce, R. D., Subbian, V., Romero, A. V., Gephart, S. M., & Malone, D. C. (2022) · Drug Safety · doi:10.1007/s40264-022-01265-1 · Cited by 57
“5 mg/day) following myocardial infarction, few DDIs have been observed [2].”
BackgroundZhang, J., Jia, J., Lai, R., Wang, X., Chen, X., Tian, W., Liu, Q., Li, J., Ju, J., & Xu, H. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1044329 · Cited by 57
Bonfioli, G. B., Rodella, L., Metra, M., & Vizzardi, E. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10450-6 · Cited by 65
Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies
Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P. K., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052196 · Cited by 72
“The COLCOT trial [161] demonstrated the efficacy of colchicine in reducing cardiovascular events in post-myocardial infarction patients, while the LoDoCo2 trial [162] confirmed its benefits in patients with chronic stable coronary artery disease.”
Fiolet, A. T. L., Silvis, M. J. M., Opstal, T. S. J., Bax, W. A., van der Horst, F. A. L., Mosterd, A., de Kleijn, D. P. V., & Cornel, J. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237665 · Cited by 58
Andreis, A., Imazio, M., Avondo, S., Casula, M., Paneva, E., Piroli, F., & Ferrari, G. M. D. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001157 · Cited by 58
Yuan, D., Jiang, P. X., Zhu, P., Jia, S., Zhang, C., Liu, Y., Liu, R., Xu, J., Tang, X., Zhao, X., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01335-1 · Cited by 58
Impact of Acute and Chronic Psychosocial Stress on Vascular Inflammation
Hinterdobler, J., Schunkert, H., Kessler, T., & Sager, H. B. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0153 · Cited by 58
“However, in recent decades, a great number of experimental, epidemiological, and lately also clinical studies have convincingly shown that inflammation plays an important role in the etiology of atherosclerosis (1, 133, 163, 176).”
BackgroundAtherosclerosis is a major human killer and non-resolving inflammation is a prime suspect
Fredman, G., & MacNamara, K. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab309 · Cited by 64
“Immune cells are important responders to damage and can be recruited to areas of injury, and exuberant immune activity increases MACEs.80 Cells of myeloid origin have been shown to contribute to plaque progression and instability in animal models,81,82 and both increased neutrophils and monocytes have been linked with…”
InfluentialModern Concepts in Cardiovascular Disease: Inflamm-Aging
Puspitasari, Y. M., Ministrini, S., Schwarz, L., Karch, C., Liberale, L., & Camici, G. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.882211 · Cited by 61
“6 months, COLCOT demonstrated that low-dose colchicine reduces the risk of CV events in patients with a recent MI, mainly driven by a reduced incidence of stroke and urgent hospitalization for non-ST elevated MI or unstable angina (Tardif et al., 2019).”
Yang, T., Li, G., Wang, C., Xu, G., Li, Q., Yang, Y., Zhu, L., Chen, L., Li, X., & Yang, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02159-5 · Cited by 64
“In the COLCOT trial, in patients with recent myocardial infarction, anti-inflammatory therapy with low-dose colchicine reduced the risk of ischemic cardiovascular events compared with placebo [33].”
BackgroundChronic inflammation and vascular cell plasticity in atherosclerosis
Lin, A., Miano, J. M., Fisher, E. A. A., & Misra, A. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00569-y · Cited by 64
“…Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) clinical trials were pivotal in demonstrating that colchicine could reduce adverse cardiovascular events—within 30 days of myocardial infarction in the COLCOT trial and for patients with stable coronary atherosclerosis in the LoDoCo2 trial 8,9 .”
Klooster, C. C. V. ’., van der Graaf, Y., Ridker, P. M., Westerink, J., Hjortnaes, J., Sluijs, I., Asselbergs, F. W., Bots, M. L., Kappelle, L. J., & Visseren, F. L. J. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.022 · Cited by 58
Johnson, T. M., Sayles, H. R., Baker, J. F., George, M., Roul, P., Zheng, C., Sauer, B. C., Liao, K. P., Anderson, D. R., Mikuls, T. R., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220125 · Cited by 56
Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
Melnikov, I., Kozlov, S. G., Saburova, O., Avtaeva, Y., Guria, K. G., & Ахнафович, Г. З. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032079 · Cited by 59
Perera, B., Wu, Y., Nguyen, N., & Ta, H. T. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100767 · Cited by 63
Colchicine in acutely decompensated heart failure: the COLICA trial
Pascual-Figal, D. A., Núñez, J. E., Pérez-Martínez, M. T., González‐Juanatey, J. R., Urquía, M. T., Llàcer, P., Delgado, J. F., Villar, S., Mirabet, S., Aimo, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae538 · Cited by 63
Mechanisms of diabetic cardiomyopathy: Focus on inflammation
Bellemare, M., Bourcier, L., Iglesies‐Grau, J., Boulet, J., O’Meara, E., & Bouabdallaoui, N. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16242 · Cited by 71
The Interplay Between Immunity, Inflammation and Endothelial Dysfunction
Chee, Y. J., Dalan, R., & Cheung, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041708 · Cited by 70
“After a median follow-up of approximately two years, the colchicine group had a 23% reduction in major cardiovascular events compared to the placebo when colchicine was initiated among individuals who had suffered from an acute myocardial event within the preceding 30 days [241].”
InfluentialOmega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
Pisaniello, A. D., Psaltis, P. J., King, P. M., Liu, G., Gibson, R. A., Tan, J. T. M., Duong, M., Nguyen, T., Bursill, C. A., Worthley, M. I., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.003 · Cited by 64
Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention
Ridker, P. M. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107238 · Cited by 51
Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities
van Veelen, A., van der Sangen, N. M. R., Delewi, R., Beijk, M. A. M., Henriques, J. P. S., & Claessen, B. E. P. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051361 · Cited by 58
“studied in the LoDoCo2 trial and COLCOT trial [157,158], and the interleukin-1-beta antagonist canakinumab, studied in the CANTOS trial [159], are able to reduce the risk for cardiac events.”
BackgroundMosaic theory revised: inflammation and salt play central roles in arterial hypertension
Hengel, F. E., Bénitah, J., & Wenzel, U. O. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00851-8 · Cited by 59
“Similarly, continued colchicine treatment after MI decreased the risk of ischemic cardiovascular events [102].”
BackgroundGirard, D., & Vandiedonck, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991716 · Cited by 58
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
Morfino, P., Aimo, A., Castiglione, V., Gálvez‐Montón, C., Emdin, M., & Bayés‐Genís, A. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10279-x · Cited by 72
“The COLCOT (COLCHICINE Cardiovascular Outcomes Trial) study, which randomized 4745 patients with MI to colchicine or placebo, revealed a lower risk of ischemic cardiovascular events at 30 days from MI in the treated group [53, 54].”
MethodBenz, A. P., Amit, G., Connolly, S. J., Singh, J., Acosta‐Vélez, J. G., Conen, D., Deif, B., Divakaramenon, S., McIntyre, W. F., Mtwesi, V., et al. (2023) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.123.012387 · Cited by 54
“9,10 We evaluated a 10-day treatment with colchicine in patients undergoing catheter ablation for AF in a randomized, double-blind, placebo-controlled clinical trial.”
MethodLi, S., Li, F., Wang, Y., Li, W., Wu, J., Hu, X.-B., Tang, T., & Liu, X. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2298514 · Cited by 55
“A large clinical trial has demonstrated that low-dose anti-inflammatory colchicine has a notable impact in reducing primary endpoint events in individuals who have recently experienced or previously suffered from Mi when compared to a placebo (tardif et al., 2019).”
BackgroundCanonical and non-canonical roles of complement in atherosclerosis
Maffia, P., Mauro, C., Case, A. G., & Kemper, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01016-y · Cited by 54
“Anti-inflammatory therapies, such as canakinumab 187 (a monoclonal antibody to IL-1β) and colchicine 188,189 , have been shown to reduce the risk of recurrent cardiovascular events in patients with previous MI.”
Controversies and practical management of patients with gout and chronic kidney disease
Johnson, R. J., Mandell, B. F., Schlesinger, N., Mount, D. B., Botson, J. K., Abdellatif, A. A., Rhoades, R., & Singh, J. A. (2024) · Kidney International · doi:10.1016/j.kint.2024.05.033 · Cited by 55
Clinical Updates in Coronary Artery Disease: A Comprehensive Review
Bottardi, A., Prado, G. F. A., Lunardi, M., Fezzi, S., Pesarini, G., Tavella, D., Scarsini, R., & Ribichini, F. L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164600 · Cited by 68
“…its inhibition . days) that had undergone PCI and intensive statin treatment reduced the rates of the primary end point (a composite of death from CV, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization) compared to the placebo group (HR, 0.77; 95% CI, 0.61 to 0.96; p = 0.02) [164].”
BackgroundInfluentialPro-inflammatory Cytokines in Acute Coronary Syndromes
Mourouzis, K., Oikonomou, E. K., Siasos, G., Tsalamadris, S., Vogiatzi, G., Antonopoulos, A. S., Fountoulakis, P. N., Goliopoulou, A., Papaioannou, S., & Tousoulis, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200413082353 · Cited by 60
Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19
Vitiello, A., & Ferrara, F. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118510 · Cited by 52
“Finally, in patients with an altered profibrotic state, anticoagulant therapy is necessary to avoid further serious complications [36,37].”
BackgroundCarotid Plaque Inflammation Imaged by PET and Prediction of Recurrent Stroke at 5 Years
McCabe, J. J., Camps‐Renom, P., Giannotti, N., McNulty, J. P., Coveney, S. A., Murphy, S., Barry, M. C., Harbison, J. A., Cronin, S., Williams, D. J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012909 · Cited by 54
Hyperuricemia, Gout, and the Brain—an Update
Latourte, A., Dumurgier, J., Paquet, C., & Richette, P. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-01050-6 · Cited by 55
“Several randomized controlled trials (RCT) further confirmed that drugs targeting IL-1β (canakinumab, colchicine) can improve outcomes in patients at high cardiovascular risk [20, 21].”
BackgroundInflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 54
Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities
Ryan, T. A. J., & O'Neill, L. A. J. (2022) · European Journal of Immunology · doi:10.1002/eji.202149410 · Cited by 54
Karnewar, S., Pulipaka, S., Katta, S., Panuganti, D., Neeli, P. K., Thennati, R., Jerald, M. K., & Kotamraju, S. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.012 · Cited by 53
Soni, S. S., D’Elia, A. M., Alsasa, A., Cho, S., Tylek, T., O’Brien, E. M., Whitaker, R. C., Spiller, K. L., & Rodell, C. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01113a · Cited by 56
German, C. A., Baum, S. J., Ferdinand, K. C., Gulati, M., Polonsky, T. S., Toth, P. P., & Shapiro, M. D. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100432 · Cited by 60
Impact of Reperfusion on Temporal Immune Cell Dynamics After Myocardial Infarction
Zhang, R. Y. K., Cochran, B. J., Thomas, S. R., & Rye, K. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027600 · Cited by 56
“100,105 Some immunomodulatory strategies have had early small-scale clinical success at improving cardiac function in patients with MI. 106 Cyclosporine, a calcineurin inhibitor that inhibits T lymphocyte activation, has been studied extensively as a strategy for protecting against…”
Fidler, T. P., Dunbar, A. J., Kim, E., Hardaway, B., Pauli, J., Xue, C., Abramowicz, S., Xiao, T., O’Connor, K., Sachs, N., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00405-9 · Cited by 53
Routine Spironolactone in Acute Myocardial Infarction
Jolly, S. S., d’Entremont, M.-A., Pitt, B., Lee, S. F., Mian, R. I., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stankovic, G. R., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405923 · Cited by 54
Self-citationCancer and Cardiovascular Disease
Alhuneafat, L., Guha, A., Blaes, A. H., & Konety, S. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.07.001 · Cited by 67
Baumann, A. A. W., Mishra, A., Worthley, M. I., Nelson, A. J., & Psaltis, P. J. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320938527 · Cited by 61
Fan, Y., Liu, J., Miao, J., Zhang, X., Yan, Y., Bai, L., Chang, J., Wang, Y., Wang, L., Bian, Y., et al. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114106 · Cited by 60
Molecular Imaging of Inflammation and Fibrosis in Pressure Overload Heart Failure
Glasenapp, A., Derlin, K., Gutberlet, M., Hess, A., Roß, T. L., Wester, H., Bengel, F. M., & Thackeray, J. T. (2021) · Circulation Research · doi:10.1161/circresaha.120.318539 · Cited by 53
Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective
Mangieri, A., Gallo, F., Sticchi, A., Khokhar, A. A., Laricchia, A., Giannini, F., & Colombo, A. (2020) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-020-00642-w · Cited by 52
Kaveh, A., Bruton, F. A., Buckley, C., Oremek, M. E. M., Tucker, C. S., Mullins, J. J., Taylor, J. M., Rossi, A. G., & Denvir, M. A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.579943 · Cited by 48
“Such treatments have been shown to improve clinical outcomes following myocardial infarction, but at the expense of a higher risk of infection (Ridker et al., 2017; Tardif et al., 2019).”
BackgroundCoveney, S. A., Murphy, S., Belton, O., Cassidy, T., Crowe, M., Dolan, E., de Gaetano, M., Harbison, J. A., Horgan, G. W., Marnane, M., et al. (2021) · International Journal of Stroke · doi:10.1177/1747493021995595 · Cited by 49
Georgakis, M. K., Malik, R., Burgess, S., & Dichgans, M. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.023277 · Cited by 50
The IL-1 Family and Its Role in Atherosclerosis
González, L., Rivera, K., Andía, M. E., & Martínez-Rodríguez, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010017 · Cited by 54
Immunomodulation and immunopharmacology in heart failure
Markousis‐Mavrogenis, G., Baumhove, L., Al‐Mubarak, A. A., Aboumsallem, J. P., Bömer, N., Voors, A. A., & van der Meer, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00919-6 · Cited by 52
Pink, C., Holtfreter, B., Völzke, H., Nauck, M. A., Dörr, M., & Kocher, T. (2023) · BMC Medicine · doi:10.1186/s12916-023-03139-4 · Cited by 61
“Indeed, recent results from large clinical trials have shown promising results for anti-inflammatory drugs in reducing CVD events and mortality in patients with atherosclerosis [5–7].”
ResultMolecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential
Fonseka, O., Gare, S. R., Chen, X., Zhang, J., Alatawi, N. H. O., Ross, C., & Liu, W. (2025) · Cells · doi:10.3390/cells14050324 · Cited by 54
Ali, S. A., Singh, G., & Datusalia, A. K. (2021) · Phytotherapy Research · doi:10.1002/ptr.7068 · Cited by 55
“A recent double blind, RCT in 4,745 patients suggested a low dose of colchicine (0.5 mg) reduces the risk of myo- cardial infarction when compared to placebo treated individuals (Tardif et al., 2019).”
BackgroundInfluentialThe Intriguing Role of TLR Accessory Molecules in Cardiovascular Health and Disease
Bezhaeva, T., Karper, J. C., Quax, P. H. A., & de Vries, M. R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.820962 · Cited by 50
Elliott, P. S., Kharaty, S. S., & Phillips, C. M. (2022) · Nutrients · doi:10.3390/nu14245371 · Cited by 64
“The CANTOS (n = 10,061) [147] and COLCOT (n = 4745) [148] trials both administered anti-inflammatory therapeutic agents in high-risk individuals, reporting a significant 15% reduction in cardiovascular death and 23% reduction in CVD outcomes after a median of 24- and ~22-month-follow-up, respectively.”
Chen, J., Fang, Z., Luo, Q., Wang, X., Warda, M., Das, A., Oldoni, F., & Luo, F. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01993-y · Cited by 47
“Notably, both canakinumab [61] and colchicines [62] have been shown to reduce the risk of ASCVD, with no significant impact on plasma lipid levels.”
BackgroundP2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients
Lee, S., Jeong, Y., Yun, K. H., Cho, J. Y., Gorog, D. A., Angiolillo, D. J., Kim, J. W., & Jang, Y. (2023) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2023.05.035 · Cited by 50
“Among them, colchicine has been effective in a randomized clinical trial of patients with ACS (12).”
InfluentialFan, L., Liu, J., Hu, W., Chen, Z., Lan, J., Zhang, T., Zhang, Y., Wu, X., Zhong, Z., Zhang, D., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00945-0 · Cited by 49
Brunham, L. R., Lonn, E., & Mehta, S. R. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.017 · Cited by 60
The Role of Inflammation in the Pathophysiology of Heart Failure
Amara, M., Stoler, O., & Birati, E. Y. (2025) · Cells · doi:10.3390/cells14141117 · Cited by 67
“The COLCOT (Colchicine Cardiovascular Outcomes Trial) [81] examined the effectiveness of low-dose colchicine in patients with recent MI.”
Liu, S.-L., Wu, N., Shi, H.-W., Dong, Q., Dong, Q., Gao, Y., Guo, Y., & Li, J. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01012-9 · Cited by 48
Colchicine and myocardial infarction: A review
Akodad, M., Sicard, P., Fauconnier, J., & Roubille, F. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.04.007 · Cited by 55
Self-citationT Cells in Autoimmunity-Associated Cardiovascular Diseases
Muallem, D. R., Burma, A. M., Kitakule, M. M., Luo, Y., & Mehta, N. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588776 · Cited by 50
“Over the last several decades, inflammation has emerged as a key driver of atherosclerotic CVD, as well as a major therapeutic target (3, 4).”
BackgroundUpdating concepts on atherosclerotic inflammation: From pathophysiology to treatment
Ministrini, S., Carbone, F., & Montecucco, F. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13467 · Cited by 52
Vascular aging and cardiovascular disease: pathophysiology and measurement in the coronary arteries
Cheng, D. C., Climie, R. E., Shu, M. W. S., Grieve, S. M., Kozor, R., & Figtree, G. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1206156 · Cited by 59
Psaltis, P. J., Nguyen, M. T., Singh, K., Sinhal, A. R., Wong, D. T. L., Alcock, R. F., Rajendran, S., Dautov, R. F., Barlis, P., Patel, S. A., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae191 · Cited by 45
Buch, M. H., Mallat, Z., Dweck, M. R., Tarkin, J. M., O’Regan, D. P., Ferreira, V. M., Youngstein, T., & Plein, S. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01149-x · Cited by 52
“The COLCOT (Colchicine Cardiovascular Outcomes Trial) trial demonstrated that colchicine reduces the risk of cardiovascular events after recent myocardial infarction, whereas the LoDoCo2 trial showed that colchicine has a similar effect in patients with chronic coronary disease 33,34 .”
Kim, H. K., Kim, S.-J., Gil, W. J., & Yang, C. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157090 · Cited by 65
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

